The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 259.00
Bid: 258.00
Ask: 261.00
Change: 30.50 (13.35%)
Spread: 3.00 (1.163%)
Open: 224.00
High: 260.50
Low: 224.00
Prev. Close: 228.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-FTSE 100 flat as Vodafone loss offsets gains in banks; Oxford Biomedica shines

Tue, 18th May 2021 09:23

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Oxford Biomedica rises on robust outlook

* Vodafone drops after missing earnings expectations

* FTSE 100 up 0.2%, FTSE 250 adds 0.6%
(Updates with market close)

By Shivani Kumaresan and Devik Jain

May 18 (Reuters) - London's FTSE 100 was little changed on
Tuesday as poor earnings by Vodafone offset gains in bank
stocks, while better-than-expected jobs data strengthened views
of a stronger economic recovery from a pandemic-driven crash
last year.

The blue-chip index rose 0.02%, with banks, mainly
HSBC Holdings, Lloyds Banking Group and
Standard Chartered gaining between 0.8% and 1.5%.

Consumer discretionary stocks, including Compass Group
, Kingfisher and Just Eat Takeaway.com
also provided the biggest boost to the index.

Mobile operator Vodafone Group fell 8.9% on
reporting a 1.2% drop in annual adjusted earnings, as COVID-19
hit roaming revenue and handset sales.

The domestically focussed mid-cap FTSE 250 index
climbed 0.5%.

Britain's unemployment rate fell again, to 4.8% between
January and March, and hiring rose further in April, according
to data that showed employers gearing up for the easing of
coronavirus curbs.

"A third consecutive month of falling unemployment suggests
the peak rate caused by the pandemic wasn't as high as feared",
said Sophie Griffiths, Market Analyst, UK & EMEA at OANDA.

"While the furlough scheme has succeeded in preventing a
wave of redundancies, there is little doubt the jobless rate
will rise again when it concludes in September."

Britain extended its huge job-protecting furlough programme
by five months until the end of September, covering about one in
five private-sector employees who receive 80% of their salary
for hours not worked.

The FTSE 100 has gained nearly 9.4% year-to-date as
investors flocked to energy, materials and banking stocks that
are seen benefiting the most from a stronger economic recovery
due to speedy COVID-19 vaccinations and government support.

Fund managers loaded up on UK stocks and cut exposure to
technology stocks as rising inflation and "taper tantrum" fears
leave growth stocks vulnerable to pull-backs, Bank of America's
May fund manager survey released on Tuesday found.

Among other stocks, Oxford Biomedica gained 10.4%,
to the top of the mid-cap index after it doubled the revenue
expectation from its COVID-19 vaccine supply deal with drugmaker
AstraZeneca.

Imperial Brands rose 1.5% after the tobacco company
reiterated its full-year outlook.
(Reporting by Shivani Kumaresan and Devik Jain in Bengaluru;
editing by Uttaresh.V and Jonathan Oatis)

More News
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more
22 Sep 2021 16:54

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

Read more
22 Sep 2021 09:16

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

Read more
22 Sep 2021 07:03

Oxford Biomedica swings to profit on Covid-19 vaccine sales

(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.

Read more
22 Sep 2021 07:03

Oxford Biomedica swings to profit on Covid-19 vaccine sales

(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.

Read more
21 Sep 2021 09:14

UPDATE 2-FTSE 100 recovers 1% on energy, healthcare stock boost; Entain jumps

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Kingfisher top FTSE 100 loser despite positive results* Royal Dutch Shell sells U.S. oilfield assets* Stagecoast surges on merger talks wit...

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.